$28.14$0.02 (+0.07%)
Last updated on --.

price

24 Hours+0.07%+$0.02
30 days-3.14%-$0.91
60 days+12.31%+$3.080
90 days+18.01%+$4.380

About

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Stock ticker
PFE
Company
Pfizer Inc.
Industry
Healthcare
Category
US
Stock split / reverse split
500527
Launch date
Jun 1, 1972
Listed exchange
NYSE

Financials

Q2 FY2026 Earnings
Report period: Jun 29, 2026 – Jun 29, 2026

Summary: PFE reported Revenue of 15.03B (+2.60%), beating expectations; EPS of 0.77 (-1.28%), beating expectations.

Revenue (USD)Beat15.03B+2.60%14.40B+6.18%634.57M+4.40%
EPS (USD)Beat0.77-1.29%0.68+17.58%0.09+12.90%
Financial estimates
● Actual● Estimate
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
0.510.62-0.290.47-0.04
+12,042.85%-20.92%-503.34%-9.55%-108.48%
● EPS● YoY
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
206.10B208.73B208.16B207.62B201.13B
117.08B115.64B121.39B117.21B115.64B
56.81%55.39%58.31%56.45%57.49%
● Assets● Liabilities● Ratio
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
-582.00M4.60B5.35B2.62B835.00M
+67.32%-31.45%-20.42%+11.99%+243.47%
● CFO● YoY

Shareholders

Shareholders
BLACKROCK, INC.9.29%
VANGUARD CAPITAL MANAGEMENT LLC6.53%
STATE STREET CORP5.39%
GEODE CAPITAL MANAGEMENT, LLC2.37%
VANGUARD PORTFOLIO MANAGEMENT LLC2.09%
Others74.31%
Institutions
% Owned67.93%+1.84%
Shares held3.87B+104.71M
Institutions2,954-133
% OwnedPrice
Name% OwnedChange
BLACKROCK, INC.9.29%+31.41M
VANGUARD CAPITAL MANAGEMENT LLC6.53%+2.72M
STATE STREET CORP5.39%+5.50M
GEODE CAPITAL MANAGEMENT, LLC2.37%+1.71M
VANGUARD PORTFOLIO MANAGEMENT LLC2.09%+2.50M

Dividends

Dividends
Last ex-dividend: Jul 24, 2026 Cash dividend: 0.43 USD per share
Dividend yield TTM
6.04%
Payout ratio LFY
126.47%
Frequency
Quarterly
20222023202420252026
1.601.641.681.721.29
+3.43%+5.52%+6.28%+7.04%+7.00%
Dividend amount (USD)Dividend yield
Stock splits
Launch date: Jun 1, 1972
DateRatio
Nov 17, 2020500 → 527
Jul 1, 19991 → 3
Jul 1, 19971 → 2
Jul 3, 19951 → 2
Apr 1, 19911 → 2
Jul 1, 19831 → 2

PFE conversion tables

PFEPFE
USDUSD
0.5 PFE14.07 USD
1 PFE28.14 USD
5 PFE140.7 USD
10 PFE281.4 USD
USDUSD
PFEPFE
0.5 USD0.017768 PFE
1 USD0.035537 PFE
5 USD0.17768 PFE
10 USD0.35537 PFE

More to explore

FAQ

PFE is trading at $28.14, +0.07% over the last 24 hours. Track live moves on the price chart at the top of this page.

The PFE stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. PFE is currently trading at $28.14, +0.07% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on PFE price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.

P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. PFE's P/E ratio is currently 37.55 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from PFE; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against PFE's historical range and other companies in the Healthcare sector.

Pfizer Inc.'s market cap is currently 161.98B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.